Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.44 |
| ▸ | FAP | Q12884 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336596 | 1.00 | FURIN (0.44) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL24520454 | 0.94 | FAP (0.47) | FURINFAPHTTMAP1LC3BNPY1R | |
| SCHEMBL9943152 | 0.94 | FAP (0.47) | FURINFAPHTTMAP1LC3BNPY1R | |
| SCHEMBL18244335 | 0.93 | FAP (0.40) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL18244334 | 0.93 | FAP (0.40) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL22746548 | 0.93 | FAP (0.42) | FURINFAPMAP1LC3BNPY1RNPY2R | |
| SCHEMBL24028236 | 0.93 | FAP (0.42) | FURINFAPMAP1LC3BNPY1RNPY2R | |
| SCHEMBL21883412 | 0.92 | FURIN (0.42) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL24916473 | 0.92 | FURIN (0.42) | FURINFAPHTTMAP1LC3BSMN1; SMN2 | |
| SCHEMBL22336599 | 0.91 | FAP (0.40) | FURINFAPHTTPDF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137502-A2 | PNU ANTHRACYCLINE-DERIVED LINKER-PAYLOADS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023002415-A2 | METHODS AND COMPOSITIONS FOR ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC) TREATMENT | Magenta Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| WO-2020247670-A1 | METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE DISEASES | Magenta Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020219964-A1 | CONDITIONING METHODS FOR GENE THERAPY | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219748-A2 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020146432-A1 | USE OF AN ANTI-CD45 ANTIBODY DRUG CONJUGATE (ADC) IN CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2020023559-A1 | USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023556-A1 | USE OF ANTI-CD137 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2020023561-A1 | USE OF ANTI-CD5 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY | Magenta Therapeutics, Inc. (US) | 2020-01-30 | — | — | WO | disclosed |